KDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE. Supplemental Tables November 2013

Size: px
Start display at page:

Download "KDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE. Supplemental Tables November 2013"

Transcription

1 KDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE Supplemental Tables November 2013

2 Suppl Table 1: Summary table of RCT examining the effect of exercise in CKD 5HD patients [continuous outcomes] Suppl Table 2: Summary table of RCT examining low vs. moderate protein diet in CKD patients without [categorical outcomes] Suppl Table 3: Summary table of RCT examining low vs. moderate protein diet in CKD patients without [continuous outcomes] Suppl Table 4: Summary table of RCT examining statin therapy vs. lifestyle modification in kidney transplant recipients without [categorical outcomes] Suppl Table 5: Summary table of RCT examining statin therapy vs. lifestyle modification in kidney transplant recipients without [continuous outcomes] Suppl Table 6: Summary table of RCT examining statin therapy vs. usual care in patients with CKD without [categorical outcomes] Suppl Table 7: Summary table of RCT examining statin therapy vs. usual care in patients with CKD without [continuous outcomes] Suppl Table 8: Summary table of RCTs of statins vs. placebo in patients with CKD with a without [categorical outcomes] Suppl Table 9: Summary table of RCTs of statins vs. placebo in various stages of CKD with a without [continuous outcomes] Suppl Table 10: Evidence profile of RCTs examining the effect of statins vs. placebo in patients with CKD with a without Suppl Table 11: Summary table of RCTs of statins vs. placebo in dialysis patients with a without [categorical outcomes] Suppl Table 12: Summary table of RCTs of statins vs. placebo in dialysis patients with a without [continuous outcomes] Suppl Table 13: Evidence profile of RCTs examining the effect of statins vs. placebo in dialysis patients with a without Suppl Table 14: Summary table of RCT examining statin vs. placebo in patients with ADPKD [continuous outcomes] Suppl Table 15: Summary table of RCT examining simvastatin/ezetimibe combination vs. simvastatin/placebo in CKD patients without [categorical outcomes] Suppl Table 16: Summary table of RCT examining simvastatin/ezetimibe combination vs. simvastatin/placebo in CKD patients without [continuous outcomes] Suppl Table 17: Summary table of RCT of statin + ezetimibe vs. placebo in CKD patients [categorical outcomes] Suppl Table 18: Summary table of RCT examining the effect of dose of atorvastatin in CKD patients with [categorical outcomes] Suppl Table 19: Drug interactions Suppl Table 20: Effects of grapefruit juice on statin pharmacokinetics a recommeations Suppl Table 21: Patients on statin + fibrate therapy reporting any adverse event Suppl Table 22: Patients receiving statin + fibrate therapy reporting other iividual adverse events Suppl Table 23: Patients on statin + fibrate therapy reporting treatment related adverse events Suppl Table 24: Patients on statin + fibrate therapy discontinuing due to adverse events Suppl Table 25: Patients on statin + fibrate therapy with increased ALT or AST Suppl Table 26: Patients on statin + fibrate therapy with increased CK Suppl Table 27: Patients on statin + fibrate therapy with increased serum creatinine Suppl Table 28: Patients receiving statin + fibrate therapy reporting rhabdomyolysis Suppl Table 29: Summary table of RCTs of statin vs. placebo in kidney transplant patients [categorical outcomes] Suppl Table 30: Summary table of RCTs of statin vs. placebo in kidney transplant patients [continuous outcomes] Suppl Table 31: Evidence profile of RCTs examining the effect of statins vs. placebo in kidney transplant recipients Suppl Table 32: Summary table of RCTs of statins vs. placebo in children with CKD without [continuous outcomes]

3 Supplemental Table 1: Summary table of RCT examining the effect of exercise in CKD 5HD patients [continuous outcomes] (Units) Lipid levels Author, Year Description No. Analyzed (Enrolled) Control Control GFR or SCr Proteinuria (Control) Results (Lipids) Final (Control) (Control) Net (95% CI) P value Quality Total cholesterol, mmol/l van Vlsteren 2005 The Netherlas 1 3 mo (3 mo) Exercise program Control 53 (60) 43 (43) CKD 5HD 4.6 (4.7) 4.6 (4.6) 0 (-0.1) 0.1 Supplemental Table 2: Summary table of RCT examining low vs. moderate protein diet in CKD patients without [categorical outcomes] Mortality All-cause mortality ESRD Author, Year Cianciaruso 2009 Italy 2 Cianciaruso 2009 Italy 2 4 y (3 y) 4 y (3 y) Description No. Analyzed (Enrolled) Results Control Control GFR Low-protein diet Low-protein diet Moderateprotein diet Moderateprotein diet 212 (212) 212 (212) 211 (211) 211 (211) 16 (17) ml/min/ 1.73 m 2 16 (17) ml/min/ 1.73 m 2 (%) 11 (13) 11 (13) TC LDL HDL Tg 125 (124) 125 (124) Events 23 (11%) [25 (12%)] 42 (20) [41 (19)] RR/OR/HR (95% CI) 1 HR 1.12 (0.64, 1.99) HR 1.00 (0.65, 1.55) P value Quality 1 Adjusted for age, sex, comorbidity score iex, a basal estimated glomerular filtration rate; as well as time-variant covariates including estimated glomerular filtration rate, protein intake, serum phosphate level, therapy with erythropoiesis-stimulating agents, a therapy with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or both. 3

4 Supplemental Table 3: Summary table of RCT examining low vs. moderate protein diet in CKD patients without [continuous outcomes] Lipid levels LDL, Author, Year Cianciaruso 2009 Italy 2 6 mo (3 y) 1 y (3 y) 2 y (3 y) 2 y (3 y) 3 y (3 y) 3 y (3 y) 4 y (3 y) 4 y (3 y) Description No. Analyzed (Enrolled) Results (Lipids) Control Control GFR Low-protein diet Moderateprotein diet 206 (212) 199 (212) 189 (212) 181 (212) 167 (212) 146 (212) 132 (212) 127 (212) 198 (211) 191 (211) 187 (211) 178 (211) 164 (211) 147 (211) 139 (211) 124 (211) 16 (17) ml/min/ 1.73 m 2 (%) 11 (13) (Control) 125 (124) Final (Control) 118 (122) 118 (120) 116 (115) 111 (123) 110 (121) 118 (124) 112 (121) 113 (111) (Control) -7 (-2) -7 (-4) -9 (-9) -14 (-1) -15 (-3) (3) -12 (-13) Net (95% CI) -5 (-13, 3) -3 (-10, 5) 0 (-7, 7) -13 (-21, -5) -12 (-20, -4) -7 (-15, 1) -10 (-17, 2) 1 (-7, 9) P value Quality (0.07)

5 Supplemental Table 4: Summary table of RCT examining statin therapy vs. lifestyle modification in kidney transplant recipients without [categorical outcomes] CV events Focal cerebellar infarctions Author, Year Nart 2009 Turkey 3 4 y (4 y) Description No. Analyzed (Enrolled) Control Control GFR or SCr Fluvastatin 40 mg NCEP modified Step 1 diet 90 (90) * Results are for adjusted analysis if provided. If unadjusted results are different please annotate. 53 (53) GFR 71.3 (69.7) ml/min SCr 1.32 (1.43) (%) TC LDL HDL Tg 231 (187) 135 (99) () 63 (56) 170 (139) Events 2 (2%) Results RR/OR/HR (95% CI) P value Quality Supplemental Table 5: Summary table of RCT examining statin therapy vs. lifestyle modification in kidney transplant recipients without [continuous outcomes] Lipid levels LDL, HDL, Triglycerides, Total cholesterol, Author, Year Nart 2009 Turkey 3 Description No. Analyzed (Enrolled) Control Control GFR or SCr (%) (Control) 1 y (4 y) 4 y 135 (99.2) (4 y) 1 y (4 y) 4 y NCEP GFR 71.3 (69.7) 63 (56) (4 y) Fluvastatin modified ml/min 1 y 40 mg Step 1 (90) (53) SCr y (4 y) diet (1.43) 170 (139) (4 y) 1 y (4 y) y (187.3) (4 y) Results (Lipids) Final (Control) (96.2) (101.3) 53.2) (49.2) 48.9 (46.1) (143.4) (145.3) (172.7) (177.7) (Control) (-3.0) (+2.1) -9.7 (-6.5) (-9.6) -0.6 (+4.7) -7.3 (+6.6) (-14.6) (-9.6) Net (95% CI) P value Quality < <

6 Supplemental Table 6: Summary table of RCT examining statin therapy vs. usual care in patients with CKD without [categorical outcomes] Composite outcome ESRD or Halving of GFR ESRD or 25% decline in GFR Kidney function ESRD Author, Year ALLHAT (CKD subgp) Rahman 2008 Multi 4 ALLHAT (CKD subgp) Rahman 2008 Multi 4 () () Description No. Analyzed (Enrolled) Control Control GFR or SCr Pravastatin 40 mg/d Pravastatin 40 mg/d Usual care Usual care 779 (779) 779 (779) * Results are for adjusted analysis if provided. If unadjusted results are different please annotate. 778 (778) 778 (778) GFR 50.8 (50.6) ml/min/1.73 m 2 GFR 50.8 (50.6) ml/min/1.73 m 2 (%) 32 (30) TC LDL HDL Tg 226 (224) 226 (224) 147 (145) 147 (145) () 46 (46) 2 46 (46) (164) 165 (164) Events 52 (7) [50 (6)] 156 (20) [154 (20]) 32 (4) [31 (4)] Results RR/OR/HR (95% CI) RR 0.97 (0.66, 1.43) RR 0.98 (0.79, 1.22) RR 1.05 (0.64, 1.73) P value Quality Estimated from graph 3 Study is graded however consider downgrading in EP due to the fact that there was no significant interaction of baseline egfr a treatment group. 4 Study is graded however consider downgrading in EP due to the fact that there was no significant interaction of baseline egfr a treatment group. 5 Estimated from graph 6 Study is graded however consider downgrading in EP due to the fact that there was no significant interaction of baseline egfr a treatment group. 6

7 Supplemental Table 7: Summary table of RCT examining statin therapy vs. usual care in patients with CKD without [continuous outcomes] Lipid levels Total cholesterol, HDL, Author, Year ALLHAT (CKD subgp) Rahman 2008 Multi 4 () Description No. Analyzed (Enrolled) Control Control GFR or SCr Pravastatin 40 mg/d Usual care 779 (779) 778 (778) GFR 50.8 (50.6) ml/min/1.73 m 2 (%) 32 (30) (Control) 226 (224) 46 (46) 9 Results (Lipids) Final (Control) 178 (198) 7 56 (38) 10 (Control) (-26.1) +10 (-8) Net (95% CI) P value Quality Estimated from graph 8 Study is graded however consider downgrading in EP due to the fact that there was no significant interaction of baseline egfr a treatment group. 9 Estimated from graph 10 Estimated from graph 11 Study is graded however consider downgrading in EP due to the fact that there was no significant interaction of baseline egfr a treatment group. 7

8 Supplemental Table 8: Summary table of RCTs of statins vs. placebo in patients with CKD with a without [categorical outcomes] CKD with Composite outcomes Coronary heart disease death, nonfatal MI, CABG, or PTCA (primary) Coronary heart disease death, nonfatal MI, CABG, PTCA, or stroke Coronary heart disease death or nonfatal MI Mortality All-cause mortality Author, Year CARE, LIPID, WOSCOPS (CKD subgp) Tonelli 2005 Multi 5 CARE, LIPID, WOSCOPS (CKD subgp) Tonelli 2005 Multi 5 () () Description No. Analyzed (Enrolled) Results Control Control Pravastatin Pravastatin 571 (571) 571 (571) GFR or SCr egfr 58 ml/min/1.73 m 2 SCr 1.3 egfr 58 ml/min/1.73 m 2 SCr 1.3 (%) 100 (100) 100 (100) TC LDL HDL Tg Events RR/OR/HR (95% CI) HR (0.57, 0.98) HR (0.62, 1.03) HR (0.60, 1.18) HR (0.69, 1.39) P value Quality <0.05 (0.06) 12 Hazards ratio have been adjusted for age; SBP; HDL; LDL; triglyceride; an iicator for trial (CARE, LIPID, or WOSCOPS); current smoking status; history of stroke; history of coronary disease; insulin depeence; a baseline use of aspirin, β blockers, ACEi, a CCB 13 Hazards ratio have been adjusted for age; SBP; HDL; LDL; triglyceride; an iicator for trial (CARE, LIPID, or WOSCOPS); current smoking status; history of stroke; history of coronary disease; insulin depeence; a baseline use of aspirin, β blockers, ACEi, a CCB 14 Hazards ratio have been adjusted for age; SBP; HDL; LDL; triglyceride; an iicator for trial (CARE, LIPID, or WOSCOPS); current smoking status; history of stroke; history of coronary disease; insulin depeence; a baseline use of aspirin, β blockers, ACEi, a CCB 15 Hazards ratio have been adjusted for age; SBP; HDL; LDL; triglyceride; an iicator for trial (CARE, LIPID, or WOSCOPS); current smoking status; history of stroke; history of coronary disease; insulin depeence; a baseline use of aspirin, β blockers, ACEi, a CCB 8

9 All cause mortality CV events CABG or PTCA Any stroke Author, Year CARDS (CKD subgp) Colhoun, 2009 UK Irela 6 CARE, LIPID, WOSCOPS (CKD subgp) Tonelli 2005 Multi 5 4 y (4 y) () Description No. Analyzed (Enrolled) Results Control Control Atorvastatin Pravastatin 482 (482) 571 (571) 488 (488) GFR or SCr egfr 53.5 (54.1) ml/min/1. 73 m 2 egfr 58 ml/min/1.73 m 2 SCr 1.3 (%) 100 (100) 100 (100) TC LDL HDL Tg 210 (212) 120 (120) 56 (56) 600 ( 60 0) Events 27 (6%) [30 (6%)] RR/OR/HR (95% CI) HR (0.51, 1.45) HR (0.47, 1.01) HR (0.63,1.97) P value (0.06) Quality Major CV disease Stroke CARDS (CKD subgp) Calhoun, 2009 UK Irela 6 Coronary heart disease Coronary revascularizatio n CKD without Composite outcomes 4 y (4 y) Atorvastatin 482 (482) 488 (488) egfr 53.5 (54.1) ml/min/1. 73 m (100) 210 (212) 120 (120) 56 (56) 600 ( 60 0) 25 (5%) [42 (9%)] 6 (1%) [15 (3%)] 18 (4%) [27 (6%)] 5 (1%) [12 (2%)] HR (0.35, 0.94) HR (0.15, 0.99) HR (0.36, 1.17) HR (0.14, 1.15) (0.07) 16 Adjusted for age, sex a treatment group 17 Hazards ratio have been adjusted for age; SBP; HDL; LDL; triglyceride; an iicator for trial (CARE, LIPID, or WOSCOPS); current smoking status; history of stroke; history of coronary disease; insulin depeence; a baseline use of aspirin, β blockers, ACEi, a CCB 18 Hazards ratio have been adjusted for age; SBP; HDL; LDL; triglyceride; an iicator for trial (CARE, LIPID, or WOSCOPS); current smoking status; history of stroke; history of coronary disease; insulin depeence; a baseline use of aspirin, β blockers, ACEi, a CCB 19 Adjusted for age, sex a treatment group 20 Adjusted for age, sex a treatment group 21 Adjusted for age, sex a treatment group 22 Adjusted for age, sex a treatment group 9

10 Nonfatal MI, nonfatal stroke, hospital stay for unstable angina, arterial revascularizatio n, or confirmed CV death (primary) MI, stroke, or confirmed CV death Nonfatal MI, nonfatal stroke, hospital stay for unstable angina, arterial revascularizatio n, or confirmed CV death a all-cause mortality Nonfatal MI, nonfatal stroke, hospital stay for unstable angina, arterial revascularizatio n, or confirmed CV death a all-cause mortality a venous thromboemboli sm Author, Year JUPITER Ridker 2010 Multi 7 2 y (2 y) Description No. Analyzed (Enrolled) Results Control Control Rosuvastati n 1638 (1638) 1629 (1629) GFR or SCr egfr 56 ml/min/1. 73 m 2 (%) 0 TC LDL HDL Tg Events 40 (2%) [71 (4%)] 24 (2%) [40 (3%)] 64 (4%) [114 (7%)] 69 (4%) [127 (8%)] RR/OR/HR (95% CI) HR 0.55 (0.38, 0.82) HR 0.59 (0.36, 0.99) HR 0.55 (0.41, 0.75) HR 0.53 (0.40, 0.71) P value Quality <

11 Coronary heart disease death, nonfatal MI, CABG, or PTCA (primary) Coronary heart disease death, nonfatal MI, CABG, PTCA, or stroke Coronary heart disease death or nonfatal MI First primary CV event including cardiac death, nonfatal MI, resuscitated cardiac arrest, cardiac revascularizatio n or unstable angina requiring hospitalization Nonfatal MI or cardiac death Author, Year CARE, LIPID, WOSCOPS (CKD subgp) Tonelli 2005 Multi 5 ALLIANCE (CKD subgp) Koren 2009 US 8 Median () () Description No. Analyzed (Enrolled) Results Control Control Pravastain Atorvastatin Usual care 286 (286) 4099 (4099) 293 (293) GFR or SCr egfr 56.5 ml/min/1. 73 m 2 SCr 1.3 egfr 51.3 (51.1) ml/min/1. 73 m 2 (%) 0 30 (26) TC LDL HDL Tg Events (227) 148 (146) 40 (40) 200 (207) 78 (27%) [105 (36%)] 32 (11%) [54 (18%)] RR/OR/HR (95% CI) HR (0.68, 0.87) HR (0.71, 0.90) HR (0.73, 1.00) HR 0.72 (0.54, 0.97) HR 0.55 (0.35, 0.85) P value Quality <0.05 < Hazards ratio have been adjusted for age; SBP; HDL; LDL; triglyceride; an iicator for trial (CARE, LIPID, or WOSCOPS); current smoking status; history of stroke; history of coronary disease; insulin depeence; a baseline use of aspirin, β blockers, ACEi, a CCB 24 Hazards ratio have been adjusted for age; SBP; HDL; LDL; triglyceride; an iicator for trial (CARE, LIPID, or WOSCOPS); current smoking status; history of stroke; history of coronary disease; insulin depeence; a baseline use of aspirin, β blockers, ACEi, a CCB 25 Hazards ratio have been adjusted for age; SBP; HDL; LDL; triglyceride; an iicator for trial (CARE, LIPID, or WOSCOPS); current smoking status; history of stroke; history of coronary disease; insulin depeence; a baseline use of aspirin, β blockers, ACEi, a CCB 11

12 CV mortality a hospitalization for CV morbidity (primary) Author, Year PREVEND IT Asselbergs 2004 Netherlas 9 4 y (4 y) Description No. Analyzed (Enrolled) Results Control Control Pravastatin 433 (433) 431 (431) GFR or SCr SCr 91 (90) µmol/l (%) 3 (2) TC LDL HDL Tg 5.8 (5.8) mmol/ L 4.1 (4.0) mmol /L 1.0 (1.0) mm ol/l 1.4 (1.3) mmol /L Events 22 (5%) [25 (6%)] RR/OR/HR (95% CI) HR 0.87 (0.49, 1.57) P value Quality Cardiac death or MI All cause death or MI Unstable angina, fatal a nonfatal MI, a sudden death Mortality All-cause mortality LIPS (CKD subgp) Lemos 2005 Multi 10 AFCAPS/Te xcaps (CKD subgp) Kerick 2010 US 11 JUPITER Ridker 2010 Multi 7 4 y (4 y) () 2 y (2 y) Fluvastatin Lovastatin Rosuvastati n 150 (150) 145 (145) 1638 (1638) 160 (160) 159 (159) 1629 (1629) SCr 1.33 CrCl <47 ml/min GFR 53 (53) ml/min/1. 73 m 2 SCr 1.4 (1.4) egfr 56 ml/min/1. 73 m 2 Total (2) (220) 151 (151) 39 (39) 177 (168) (5%) [13 (8%)] 7 (5%) [13 (8%)] 5 (3.4%) 17 (7.5%) 34 (2%) [61 (4%)] RR 0.57 (0.24, 1.40) RR 0.57 (0.24, 1.40) RR 0.32 (0.10, 1.11) HR 0.56 (0.37, 0.85) (0.06) Study graded due to unbalance in baseline characteristics. No info on treatment vs. placebo among the 310 renal impairment patients. Consider downgrading further in EP due to being unable to locate interaction results. 27 Study graded due to unbalance in baseline characteristics. No info on treatment vs. placebo among the 310 renal impairment patients. Consider downgrading further in EP due to being unable to locate interaction results. 28 Study is graded, however consider downgrading in EP due to the fact that for all clinical events, the effects of lovastatin did not differ significantly between subgroups with a without CKD(P>0.1) for all interaction tests. 12

13 All-cause mortality Author, Year CARE, LIPID, WOSCOPS (CKD subgp) Tonelli 2005 Multi 5 () Description No. Analyzed (Enrolled) Results Control Control Pravastain 4099 (4099) GFR or SCr egfr 56.5 ml/min/1. 73 m 2 SCr 1.3 (%) 0 TC LDL HDL Tg Events RR/OR/HR (95% CI) HR (0.82, 1.15) P value Quality All-cause mortality All-cause mortality ALLIANCE (CKD subgp) Koren 2009 US 8 PREVEND IT Asselbergs 2005 Netherla 9 s () 4 y (4 y) Atorvastatin Pravastatin Usual care 286 (286) 433 (433) 293 (293) 431 (431) egfr 51.3 (51.1) ml/min/1. 73 m 2 SCr 91 (90) µmol/l 30 (26) 3 (2) 228 (227) 5.8 (5.8) mmol/ L 148 (146) 4.1 (4.0) mmol /L 40 (40) 1.0 (1.0) mm ol/l 200 (207) 1.4 (1.3) mmol /L 47 (16%) [59 (20%)] 6 (1%) [4 (1%)] RR 0.82 (0.58, 1.15) 30 RR 1.49 ( ) 31 All-cause mortality Noncardiac death LIPS (CKD subgp) Lemos 2005 Multi 10 4 y (4 y) Fluvastatin 150 (150) 160 (160) SCr 1.33 CrCl <47 ml/min Total (2%) [3 (2%)] RR 1.07 (0.22, 5.20) Hazards ratio have been adjusted for age; SBP; HDL; LDL; triglyceride; an iicator for trial (CARE, LIPID, or WOSCOPS); current smoking status; history of stroke; history of coronary disease; insulin depeence; a baseline use of aspirin, β blockers, ACEi, a CCB 30 Calculated by the ERT 32 Study graded due to unbalance in baseline characteristics. No info on treatment vs. placebo among the 310 renal impairment patients. Consider downgrading further in EP due to being unable to locate interaction results. 33 Study graded fair due to unbalance in baseline characteristics. No info on treatment vs. placebo among the 310 renal impairment patients. Consider downgrading further in EP due to being unable to locate interaction results. 13

14 All-cause mortality (primary) Total mortality CV Mortality Death from CHD or nonfatal MI (primary) Total mortality Cardiac death Author, Year 4S (CKD subgp) Chonchol 2007 Scainavia n countries 12 MEGA (CKD subgp) Nakamura 2009 Japan 13 CARE (CKD subgp) Tonelli 2003 US & Canada 14 LIPS (CKD subgp) Lemos 2005 Multi 10 () () () 4 y (4 y) Description No. Analyzed (Enrolled) Results Control Control Simvastatin Pravastatin + NCEP Step 1 Diet Pravastatin Fluvastatin NCEP Step 1 Diet 1143 (1143) 1462 (1462) 844 (844) 150 (150) 1171 (1171) 1516 (1516) 867 (867) 160 (160) GFR or SCr GFR 65.2 (65.2) ml/min) 34 SCr 1.15 (1.14) GFR 52.6 (52.5) ml/min/m 2 CrCl 61.2 (61.3) ml/min 37 Scr 61.2 (61.3) µmol/l SCr 1.33 CrCl CrCl <47 ml/min (%) 5 (4) Total (15) TC LDL HDL Tg 261 (261) 6.3 mmol/ L 209 (209) 189 (189) 4.0 mmol /L 138 (139) 46 (46) 1.5 mm ol/l 41 (41) 131 (134) 1.5 mmol /L 149 (149) Total Events Total 246 (11%) 16 (1%) [34 (2%)] 89 (11%) [126 (15%)] 86 (10%) [111 (13%)] 3 (2%) [3 (2%)] RR/OR/HR (95% CI) HR 0.69 (0.54, 0.89) HR 0.49 (0.27, 0.89) HR (0.55, 0.95) HR (0.61, 1.08) RR 1.07 (0.22, 5.20) P value Quality Mild chronic renal insufficiency is defined as egfr <75 ml/min/1.73m 2 (<1.25 ml/s) or creatinine clearance <75 ml/min (1.25 ml/s) 35 Study is graded however consider downgrading in EP due to inconsistency in interaction test results (P=0.05 for total mortality a P=0.84 for major coronary events). 36 Study is graded due to the fact that baseline characteristics by intervention were not provided in the CKD subgroup. Consider downgrading again in EP due to not being able to fi interaction results. 37 Mild chronic renal insufficiency is defined as creatinine clearance <75 ml/min 38 Adjusted for age; sex; history of HTN; smoking at baseline; ; previous CHF; use of ACEi, CCB, β-adrenergic blockers, a aspirin; proteinuria; SBP a DBP; baseline HDL a LDL, cholesterol levels; baseline Tg; serum albumin levels; BSA; a pravastatin use. 39 Adjusted for age; sex; history of HTN; smoking at baseline; ; previous CHF; use of ACEi, CCB, β-adrenergic blockers, a aspirin; proteinuria; SBP a DBP; baseline HDL a LDL, cholesterol levels; baseline Tg; serum albumin levels; BSA; a pravastatin use. 40 Study graded due to unbalance in baseline characteristics. No info on treatment vs. placebo among the 310 renal impairment patients. Consider downgrading further in EP due to being unable to locate interaction results. 14

15 CV mortality CV mortality Author, Year AFCAPS/Te xcaps (CKD subgp) Kerick 2010 US 11 PREVEND IT Asselbergs 2005 Netherlas 9 () 4 y (4 y) Description No. Analyzed (Enrolled) Results Control Control Lovastatin Pravastatin 145 (145) 433 (433) 159 (159) 431 (431) GFR or SCr GFR 53 (53) ml/min/1. 73m 2 SCr 1.4 (1.4) SCr 91 (90) µmol/l (%) 1 (2) 3 (2) TC LDL HDL Tg 224 (220) 5.8 (5.8) mmol/ L 151 (151) 4.1 (4.0) mmol /L 39 (39) 1.0 (1.0) mm ol/l 177 (168) 1.4 (1.3) mmol /L Events [1 (0.6%)] 4 (1%) [4 (1%)] RR/OR/HR (95% CI) P value Quality CV events MI Stroke Arterial revascularizatio n Venous thromboemboli sm Major coronary event Fatal MI or confirmed nonfatal MI JUPITER Ridker 2010 Multi 7 CARE Tonelli 2003 US & Canada 14 2 y (2 y) () Rosuvastatin Pravastatin 1638 (1638) 844 (844) 1629 (1629) 867 (867) egfr 56 ml/min/1. 73 m 2 CrCl 61.2 (61.3) ml/min 42 Scr 61.2 (61.3) 0 13 (15) (209) 138 (139) 41 (41) 149 (149) 8 (1%) [20 (1%)] 10 (1%) [14 (1%)] 19 (1%) [39 (1%)] 6 (0.3%) [17 (1%)] 171 (20%) [234 (27%)] 65 (8%) [90 (10%)] HR 0.40 (0.17, 0.90) HR 0.71 (0.31, 1.59) HR 0.48 (0.28, 0.83) HR 0.34 (0.14, 0.88) HR (0.59, 0.88) HR (0.52, 1.01) (0.06) 41 Study is graded, however consider downgrading in EP due to the fact that for all clinical events, the effects of lovastatin did not differ significantly between subgroups with a without CKD(P>0.1) for all interaction tests. 42 Mild chronic renal insufficiency is defined as creatinine clearance <75 ml/min 43 Adjusted for age; sex; history of HTN; smoking at baseline; ; previous CHF; use of ACEi, CCB, β-adrenergic blockers, a aspirin; proteinuria; SBP a DBP; baseline HDL a LDL, cholesterol levels; baseline Tg; serum albumin levels; BSA; a pravastatin use. 44 Adjusted for age; sex; history of HTN; smoking at baseline; ; previous CHF; use of ACEi, CCB, β-adrenergic blockers, a aspirin; proteinuria; SBP a DBP; baseline HDL a LDL, cholesterol levels; baseline Tg; serum albumin levels; BSA; a pravastatin use. 15

16 CABG or PTCA Unstable angina Stroke Major coronary event in subgroup of CKD a proteinuria Major coronary event in subgroup with CrCl >75 ml/min Major coronary event in subgroup with CrCl 75 ml/min Author, Year Description No. Analyzed (Enrolled) Results Control Control 255 (255) 1139 (1139) 844 (844) 268 (268) 1164 (1164) 867 (867) GFR or SCr (%) TC LDL HDL Tg Events µmol/l 105 (12%) [153 (18%)] 133 (16%) [142 (16%)] 29 (3%) [46 (5%)] CrCl >75 ml/min CrCl 75 ml/min Dipstick + 65 (26%) [81 (30%)] 244 (21%) [315 (27%)] 171 (20%) [234 (27%)] RR/OR/HR (95% CI) HR (0.50, 0.83) HR (0.73, 1.18) HR (0.39, 1.00) Unadjusted absolute reduction in cumulative incidence 4.7 Unadjusted absolute reduction in cumulative incidence 5.7 Unadjusted absolute reduction in cumulative incidence 6.7 P value Quality Adjusted for age; sex; history of HTN; smoking at baseline; ; previous CHF; use of ACEi, CCB, β-adrenergic blockers, a aspirin; proteinuria; SBP a DBP; baseline HDL a LDL, cholesterol levels; baseline Tg; serum albumin levels; BSA; a pravastatin use. 46 Adjusted for age; sex; history of HTN; smoking at baseline; ; previous CHF; use of ACEi, CCB, β-adrenergic blockers, a aspirin; proteinuria; SBP a DBP; baseline HDL a LDL, cholesterol levels; baseline Tg; serum albumin levels; BSA; a pravastatin use. 47 Adjusted for age; sex; history of HTN; smoking at baseline; ; previous CHF; use of ACEi, CCB, β-adrenergic blockers, a aspirin; proteinuria; SBP a DBP; baseline HDL a LDL, cholesterol levels; baseline Tg; serum albumin levels; BSA; a pravastatin use. 16

17 Major coronary event in subgroup with CrCl ml/min Major coronary event in subgroup with CrCl ml/min Major coronary event in subgroup with CrCl 60 ml/min Major coronary event in subgroup with CrCl 50 ml/min CABG or PTCA Author, Year CARE, LIPID, () Description No. Analyzed (Enrolled) Results Control Control Pravastain 524 (524) 719 (719) 320 (320) 125 (125) 4099 (4099) 518 (518) 736 (736) 349 (349) 131 (131) GFR or SCr CrCl ml/min CrCl ml/min CrCl 60 ml/min CrCl 50 ml/min egfr 56.5 (%) 0 TC LDL HDL Tg Events 103 (20%) [143 (28%)] 140 (20%) [207 (28%)] 68 (21%) [91 (26%)] 31 (25%) [27 (21%)] RR/OR/HR (95% CI) Unadjusted absolute reduction in cumulative incidence 7.9 Unadjusted absolute reduction in cumulative incidence 8.6 Unadjusted absolute reduction in cumulative incidence 4.8 P value Quality -- HR (0.61, 0.86) < Hazards ratio have been adjusted for age; SBP; HDL; LDL; triglyceride; an iicator for trial (CARE, LIPID, or WOSCOPS); current smoking status; history of stroke; history of coronary disease; insulin depeence; a baseline use of aspirin, β blockers, ACEi, a CCB 17

18 Any stroke Author, Year WOSCOPS (CKD subgp) Tonelli 2005 Multi 5 Description No. Analyzed (Enrolled) Results Control Control GFR or SCr ml/min/1. 73 m 2 SCr 1.3 (%) TC LDL HDL Tg Events RR/OR/HR (95% CI) HR (0.71, 1.30) P value Quality Non-fatal MI Stroke Cardiac death Fatal a non fatal CV events Fatal a non fatal MI Major coronary events ALLIANCE (CKD subgp) Koren 2009 US 8 AFCAPS/Te xcaps (CKD subgp) Kerick 2010 US 11 4S (CKD subgp) Chonchol () () () Atorvastatin Lovastatin Simvastatin Usual care 286 (286) 145 (145) 1143 (1143) 293 (293) 159 (159) 1171 (1171) egfr 51.3 (51.1) ml/min/1. 73 m 2 GFR 53 (53) ml/min/1. 73 m 2 SCr 1.4 (1.4) 30 (26) 1 (2) GFR 65.2 (65.2) ml/min) 55 5 (4) 228 (227) 224 (220) 261 (261) 148 (146) 151 (151) 189 (189) 40 (40) 39 (39) 46 (46) 200 (207) 177 (168) 131 (134) 17 (6%) [29 (10%)] 11 (4%) [12 (4%)] 17 (6%) [27 (9%)] 8 (6%) [21 (13%)] 2 (1%) [6 (4%)] Total (24%) HR 0.54 (0.30, 0.99) RR 0.94 (0.42, 2.09) 50 RR 0.65 (0.36,1.16) 51 RR 0.39 (0.16, 0.93) RR 0.10 (0.01, 1.32) HR 0.67 (0.56, 0.79) (0.08) Hazards ratio have been adjusted for age; SBP; HDL; LDL; triglyceride; an iicator for trial (CARE, LIPID, or WOSCOPS); current smoking status; history of stroke; history of coronary disease; insulin depeence; a baseline use of aspirin, β blockers, ACEi, a CCB 50 Calculated by the ERT 51 Calculated by the ERT 52 Fully adjusted model 53 Study is graded, however consider downgrading in EP due to the fact that for all clinical events, the effects of lovastatin did not differ significantly between subgroups with a without CKD(P>0.1) for all interaction tests. 54 Study is graded, however consider downgrading in EP due to the fact that for all clinical events, the effects of lovastatin did not differ significantly between subgroups with a without CKD(P>0.1) for all interaction tests. 55 Mild chronic renal insufficiency is defined as egfr <75 ml/min/1.73m 2 (<1.25 ml/s) or creatinine clearance <75 ml/min (1.25 ml/s) 56 Study is graded however consider downgrading in EP due to inconsistency in interaction test results (P=0.05 for total mortality a P=0.84 for major coronary events). 18

19 Nonfatal MI Author, Year 2007 Scainavia n countries 12 Description No. Analyzed (Enrolled) Results Control Control GFR or SCr SCr 1.15 (1.14) (%) TC LDL HDL Tg Events RR/OR/HR (95% CI) HR 0.65 (0.55, 0.78) P value Quality 57 Coronary revascularizatio n CV events Stroke Kidney function Doubling of SCr 25% MDRDeGFR in patients with mild CKD Acute renal failure in patients with mild CKD PREVEND IT Asselbergs 2005 Netherlas 9 MEGA (CKD subgp) Nakamura 2009 Japan 13 JUPITER Ridker 2010 Multi 7 CARE, LIPID, WOSCOPS (CKD subgp) Tonelli 2005 Multi 15 4 y (4 y) () 2 y (2 y) Median () Pravastatin Pravastatin + NCEP Step 1 Diet Rosuvastati n Pravastain NCEP Step 1 Diet 433 (433) 1462 (1462) 1638 (1638) 6479 (6479) 431 (431) 1516 (1516) 1629 (1629) 6364 (6364) SCr 91 (90) µmol/l GFR 52.6 (52.5) ml/min/m 2 egfr 56 ml/min/1. 73 m 2 egfr 73.8 (73.8) ml/min/1.73 m 2 SCr 1.08 (1.08) 3 (2) Total (6) 5.8 (5.8) mmol /L 6.3 mm ol/l 4.1 (4.0) mmol/ L 4.0 mmol/l 1.0 (1.0) mm ol/l 1.5 mm ol/l 1.4 (1.3) mmol /L 1.5 mmol /L (236) 163 (163) 40 (40) 160 (158) HR 0.62 (0.49, 0.77) 18 (4%) [21 (5%)] 8 (1%) [29 (2%)] 3 (0.2%) (10%) [ (11%)] (0.2%) [ [0.5%)] HR 0.27 (0.12, 0.59) RR 0.94 (0.85, 1.03) RR 0.42 (0.22, 0.78) Study is graded however consider downgrading in EP due to inconsistency in interaction test results (P=0.05 for total mortality a P=0.84 for major coronary events). 58 Study is graded however consider downgrading in EP due to inconsistency in interaction test results (P=0.05 for total mortality a P=0.84 for major coronary events). 59 Study is graded due to the fact that baseline characteristics by intervention were not provided in the CKD subgroup. Consider downgrading again in EP due to not being able to fi interaction results. 19

20 egfr 60 ml/min/1.73m 2 in patients with mild CKD 25% CGeGFR in patients with mild CKD egfr 25% GFR 25% Author, Year AFCAPS/Te xcaps (CKD subgp) Kerick 2010 US 11 4S (CKD subgp) Huskey 2009 Scainavia n countries 16 () 6 y (6 y) Description No. Analyzed (Enrolled) Results Control Control Lovastatin Simvastatin <6479 (<6479) 145 (145) 199 (199) <6364 (<6364) 159 (159) 210 (210) GFR or SCr GFR 53 (53) ml/min/1. 73 m 2 SCr 1.4 (1.4) GFR 55 (55) ml/min/1. 73 m 261 (%) 6 (6) 1 (2) 4 (1) TC LDL HDL Tg 224 (220) 265 (265 ) 151 (151) 192 (191) 39 (39) 47 (48) 177 (168) 133 (134) Events (27%) [ [29%)] (9%) [ (10%)] 4% [3%] 5 (3%) [13 (6%)] RR/OR/HR (95% CI) RR 0.95 (0.90, 1.00) RR 0.88 (0.78, 0.91) P value (0.06) Quality OR 0.21 (0.05, 0.94) Study is graded, however consider downgrading in EP due to the fact that for all clinical events, the effects of lovastatin did not differ significantly between subgroups with a without CKD(P>0.1) for all interaction tests. 61 Mild chronic renal insufficiency is defined as egfr <60 ml/min/1.73m 2 62 Study is graded however consider downgrading in EP due to inconsistency in interaction test results (P=0.05 for total mortality a P=0.84 for major coronary events). 20

21 Supplemental Table 9: Summary table of RCTs of statins vs. placebo in various stages of CKD with a without [continuous outcomes] (Units) CKD without Lipid levels Median LDL, Median HDL, Median Triglycerides, LDL, Total cholesterol, % Total cholesterol, LDL, % HDL, % Triglycerides, Total cholesterol, mmol/l LDL cholesterol, mmol/l Author, Year JUPITER Ridker 2010 Multi 7 CARE Tonelli US & Canada ALLIANCE (CKD subgp) Koren 2009 US 8 PREVEND IT Asselbergs 2004 Netherlas 9 2 y (2 y) () () 4 y (4 y) Description No. Analyzed (Enrolled) Results (Lipids) Control Control Rosuvastati n Pravastatin Atorvastatin Pravastatin Usual care 1638 (1638) 345 (345) 271 (286) 376 (433) 375 (433) 1629 (1629) 345 (345) 158 (293) 21 GFR or SCr egfr 56 ml/min/1.73 m 2 GFR 53.2 (52.5) ml/min/ 1.73 m 2 SCr 1.4 (1.4) egfr 51.3 (51.1) ml/min/ 1.73 m (431) SCr (431) (90) µmol/l 63 Estimated from figure 64 Estimated from figure 65 Estimated from figure 66 Results of in total cholesterol from baseline to 3 months, 1 year, 2 years a 3 years was also statistically significant. 67 Results of in LDL from baseline to 3 months, 1 year, 2 years a 3 years was also statistically significant. (%) 0 14 (17) 30 (26) 3 (2) (Control) 189 (189) 49 (49) 130 (130) (138.7) (209.9) (227.0) (146.0) 40.2 (40.3) (207.3) 5.8 (5.8) mmol/l 4.1 (4.0) mmol/l Final (Control) 55 (108) 53 (50) 99 (129) 92.2 (106.1) 4.8 (5.6) mmol/l 3.1 (3.9) mmol/l (Control) -134 (-81) 4 (1) -31 (-1) -41 () -41 () -24 (-15) (-24.2) +4 (+8) 64-8 (-4) 65-1 (-0.2) -1 (-0.1) Net (95% CI) P value Quality -53 < < < < <

22 (Units) Total cholesterol, HDL, LDL, Triglycerides, Total cholesterol, HDL, LDL, Triglycerides, Author, Year AFCAPS/Tex CAPS (CKD subgp) Kerick 2010 US 11 4S (CKD subgp) Chonchol 2007 Scainavian countries 12 () () Description No. Analyzed (Enrolled) Results (Lipids) Control Control Lovastatin Simvastatin 145 (145) 1143 (1143) 159 (159) 1171 (1171) GFR or SCr GFR 53 (53) ml/min/ 1.73 m 2 SCr 1.4 (1.4) GFR 65.2 (65.2) ml/min) 72 SCr 1.15 (1.14) (%) 1 (2) 5 (4) (Control) 224 (220) 39 (39) 151 (151) 177 (168) 261 (261) 46 (46) 189 (189) 131 (134) Final (Control) 233 (261) 52 (43) 151 (186) 115 (136) (Control) -20% (+1.5%) +7.4% (+1.1%) -27% (+1.9%) -15% (+4.2%) -28% (0%) +6% (-3%) -38% (+2%) -16% (+2%) Net (95% CI) P value Quality -18.5% % % % 71-28% 73 +3% 74-36% 75-14% Study is graded, however consider downgrading in EP due to the fact that for all clinical events, the effects of lovastatin did not differ significantly between subgroups with a without CKD(P>0.1) for all interaction tests. 69 Study is graded, however consider downgrading in EP due to the fact that for all clinical events, the effects of lovastatin did not differ significantly between subgroups with a without CKD(P>0.1) for all interaction tests. 70 Study is graded, however consider downgrading in EP due to the fact that for all clinical events, the effects of lovastatin did not differ significantly between subgroups with a without CKD(P>0.1) for all interaction tests. 71 Study is graded, however consider downgrading in EP due to the fact that for all clinical events, the effects of lovastatin did not differ significantly between subgroups with a without CKD(P>0.1) for all interaction tests. 72 Mild chronic renal insufficiency is defined as egfr <75 ml/min/1.73m 2 (<1.25 ml/s) or creatinine clearance <75 ml/min (1.25 ml/s) 73 Study is graded however consider downgrading in EP due to inconsistency in interaction test results (P=0.05 for total mortality a P=0.84 for major coronary events). 74 Study is graded however consider downgrading in EP due to inconsistency in interaction test results (P=0.05 for total mortality a P=0.84 for major coronary events). 75 Study is graded however consider downgrading in EP due to inconsistency in interaction test results (P=0.05 for total mortality a P=0.84 for major coronary events). 76 Study is graded however consider downgrading in EP due to inconsistency in interaction test results (P=0.05 for total mortality a P=0.84 for major coronary events). 22

23 Supplemental Table 10: Evidence profile of RCTs examining the effect of statins vs. placebo in patients with CKD with a without Composite outcomes Mortality CV mortality CV events ESRD Kidney function (categorical) Lipid levels (continuous) Adverse events Total Non Non # of studies a study design MA of 3 RCTs (High) MA of 3 RCTs + 5 RCTs (High) MA of 3 RCTs + 1 RCT (High) MA of 3 RCTs + 6 RCTs (High) Total N (treatment) 571 () 9423 ( ) 1541 (482 + ) ( ) Methodological quality of studies per outcome Some limitations (-1) No limitations No limitations No limitations Consistency across studies NA No important inconsistencies No important inconsistencies Important inconsistencies (-1) Directness of the evidence generalizability/ applicability Uncertainty about directness (-1) Uncertainty about directness (-1) Uncertainty about directness (-1) Uncertainty about directness (-1) 23 Other considerations None None None None Quality of evidence for outcome Low Moderate Moderate 0 RCTs Important Uncertainty about Non 4 RCTs 3186 No limitations None inconsistencies directness Low (High) (1572) (-1) (-1) Non MA of 3 RCTs + 1 RCT (High) MA of 3 RCTs + 7 RCTs (High) 1541 (482 + ) ( ) No limitations No limitations No important inconsistencies No important inconsistencies Uncertainty about directness (-1) Uncertainty about directness (-1) 0 RCTs Non 0 RCTs None None Low Moderate Moderate 0 RCTs Non MA of 3 RCTs + 3 RCTs (High) (9405) Some limitations (-1) No important inconsistencies Uncertainty about directness (-1) 0 RCTs No important Uncertainty about Non 6 RCTs 7762 No limitations None inconsistencies directness Moderate (High) (3918) (-1) MA of 3 RCTs + 8 RCTs (High) MA of 3 RCTs + 8 RCTs (High) ( ) ( ) None Low Summary of fiings Qualitative description of effect Possible benefit from statins in patients with Benefit from statins in patients without No difference in patients with Possible benefit from statins in patients without Possible benefit from statins in patients without Possible benefit from statins for patients with Benefit from statins in patients without Importance of outcome Critical Critical Critical Critical -- Critical Possible benefit from statins in patients without Benefit from statins in patients without No difference High Moderate Moderate

24 # of studies a study design Total N (treatment) Methodological quality of studies per outcome Balance of potential benefits a harms: Possible benefit Consistency across studies Directness of the evidence generalizability/ applicability Other considerations Quality of evidence for outcome Summary of fiings Qualitative description of effect Quality of overall evidence: Low Importance of outcome 24

25 Supplemental Table 11: Summary table of RCTs of statins vs. placebo in dialysis patients with a without [categorical outcomes] Dialysis with Composite outcomes Composite of cardiac death, nonfatal MI, or stroke (primary) Composite of cardiac death, nonfatal MI, or stroke for CRP quartile 1 ( 2.3 mg/l) Composite of cardiac death, nonfatal MI, or stroke for CRP quartile 2 (>2.3-5 mg/l) Composite of cardiac death, nonfatal MI, or stroke for CRP quartile 3 (> mg/l) Composite of cardiac death, nonfatal MI, or stroke for CRP quartile 4 (>12.4 mg/l) Primary outcome in 2 a 3 rd CRP quartiles combined Author, Year 4D Wanner 2005 Germany 18 4D Krane 2008 Germany 19 4 y (2 y) 4 y (2 y) Description No. Analyzed (Enrolled) Results Control Control Atorvastatin 619 (619) 316 (316) 310 (310) 312 (312) 311 (311) 622 (622) 636 (636) GFR or SCr CKD 5HD (%) 100 (100) TC LDL HDL Tg 218 (220) 125 (127) (36) 261 (267) Events 226 (37%) [243 (38%)] 60 [50] 50 [56] 52 [78] 62 [57] RR/OR/HR (95% CI) RR 0.92 (0.77, 1.10) HR 1.19 (0.81,1.76) HR 0.75 (0.50, 1.10) HR 0.79 (0.55, 1.13) HR 1.06 (0.73, 1.54) HR 0.85 (0.65, 1.10) P value Quality 25

26 Major CV event, defined as nonfatal MI, nonfatal stroke, or death from CV causes Composite cardiac epoint of cardiac death or nonfatal MI Cardiac death, nonfatal MA, fatal or nonfatal stroke Mortality Death from all causes Death from causes other than CV or cerebrovascula r disease All-cause mortality for CRP quartile 1 ( 2.3 mg/l) All-cause mortality for CRP quartile 2 (>2.3-5 mg/l) All-cause mortality for CRP quartile 3 (> mg/l) Author, Year AURORA Fellstrom subgp with 2009 Multi 20 AURORA Holdaas subgp with Multi 4D Wanner 2005 Germany 18 4D Krane 2008 Germany 19 Median 4 y (2 y) 3 y (2 y) 4 y (2 y) 4 y (2 y) Description No. Analyzed (Enrolled) Results Control Control Rosuvastati n Rosuvastati n Atorvastatin 388 (388) 388 ( (619) 316 (316) 310 (310) 312 (312) 343 (343) 343 (343) 636 (636) GFR or SCr CKD 5HD (%) 100 (100) CKD 5HD 100% CKD 5HD 100 (100) TC LDL HDL Tg 4.49 (4.35) mmol /L 218 (220) 2.51 (2.43) mmol /L 125 (127) (1.08) mmol /L 36 (36) 1.90 (1.85) mmol /L 261 (267) Events 135 (13%) [136 (15%)] 85 (22%) [104 (30%)] Risk reduction 16.2% for 297 (48) [320 (50%)] 149 (24%) [158 (25%)] 64 [55] 67 [77] 63 [94] RR/OR/HR (95% CI) RR 0.88 (0.73, 1.06) 77 HR 0.68 (0.51, 0.90) HR (0.654, 1.074) RR 0.93 (0.79, 1.08) RR 0.95 (0.76, 1.18) HR 1.07 (0.74, 1.55) HR 0.73 (0.53, 1.02) HR 0.79 (0.57, 1.11) P value Quality (0.067) 77 Calculated by ERT 26

27 All-cause mortality for CRP quartile 4 (>12.4 mg/l) All-cause mortality in 2 a 3 rd CRP quartiles combined Death from any cause CV Mortality Cardiac mortality Deaths attributable to cardiac disease Fatal cardiac events CV events Nonfatal MI Fatal stroke Nonfatal stroke All cardiac events combined All cerebrovascula r events combined Stroke Author, Year AURORA Holdaas subgp with Multi 4D Wanner 2005 Germany 18 AURORA Holdaas subgp with Multi 4D Wanner 2005 Germany 18 3 y (2 y) 4 y (2 y) 3 y (2 y) 4 y (2 y) Description No. Analyzed (Enrolled) Results Control Control Rosuvastati n Atorvastatin Rosuvastati n Atorvastatin 388 (388) 619 (619) 388 (388) 619 (619) 311 (311) 622 (622) 343 (343) 636 (636) 343 (343) 636 (636) GFR or SCr (%) CKD 5HD 100% CKD 5HD 100 (100) CKD 5HD 100% CKD 5HD 100 (100) TC LDL HDL Tg 4.49 (4.35) mmol /L 218 (220) 4.49 (4.35) mmol /L 218 (220) (2.43) mmol /L 125 (127) 2.51 (2.43) mmol /L 125 (127) 1.11 (1.08) mmol /L 36 (36) 1.11 (1.08) mmol /L 36 (36) 1.90 (1.85) mmol /L 261 (267) 1.90 (1.85) mmol /L 261 (267) Events 101 [91] 130 [171] 219 (56%) [213 (62%)] 121 (20%) [149 (23%)] 35% [47%] 64% [71%] 70 (11%) [79 (12%)] 27 (4%) [13 (2%)] 33 (5%) [32 (5%)] 205 (33%) [246 (39%)] 79 (13%) [70 (11%)] 59 (10%) [44 (7%)] RR/OR/HR (95% CI) HR 1.02 (0.77, 1.37) HR 0.78 (0.62, 0.99) HR 0.86 (0.71, 1.04) RR 0.81 (0.64, 1.03) P value Quality (0.08) RR 0.88 (0.64, 1.21) RR 2.03 (1.05, 3.93) RR 1.04 (0.64, 1.69) RR 0.82 (0.68, 0.99) RR 1.12 (0.81, 1.55) RR 1.33 (0.90, 1.97)

28 Hemorrhagic stroke Stroke Fatal stroke Hemorrhagic strokes Author, Year AURORA Fellstrom subgp with 2009 Multi 20 AURORA Holdaas subgp with Multi Dialysis without Composite outcome Time to CV event defined as a nonfatal MI, nonfatal stroke, or death from CV cause (primary) CV event defined as a nonfatal MI, nonfatal stroke, or death from CV cause (primary) Mortality Time to death from any cause Death from any cause AURORA Fellstrom 2009 Multi 20 AURORA Fellstrom 2009 Multi 20 Median 4 y (2 y) 3 y (2 y) Median 4 y (2 y) Median 4 y (2 y) Description No. Analyzed (Enrolled) Results Control Control Rosuvastati n Rosuvastati n Rosuvastati n Rosuvastati n 388 (388) 388 ( (1391) 1389 (1391) 343 (343) 343 (343) 1384 (1385) 1384 (1385) GFR or SCr CKD 5HD (%) 100 (100) CKD 5HD 100% CKD 5HD CKD 5HD 21 (18) 21 (18) TC LDL HDL Tg 4.49 (4.35) mmol /L 176 (174) 176 (174) 2.51 (2.43) mmol /L 100 (99) 100 (99) 1.11 (1.08) mmol /L 45 (45) 45 (45) 1.90 (1.85) mmol /L 157 (154) 157 (154) Events 12 (4%) [2 (1%)] 38 (10%) [20 (6%)] 18 (5%) [11 (3%)] 12 (3%) [2 (0.6%)] 9.2/100 pt-y [9.5/100 pty] 396 (29%) [408 (29%)] 13.5/100 pty [14.0/100 pty] 636 (46%) [660 (48%)] RR/OR/HR (95% CI) RR 5.30 ( ) 78 HR 1.65 (0.96, 2.83) HR 1.41 (0.67, 2.99) HR 5.21 (1.17, 23.27) P value Quality 0.07 (0.07) HR 0.96 (0.84, 1.11) HR 0.96 (0.86, 1.07) 78 Calculated by ERT 28

29 Time to death from non-cv cause Death from non-cv cause CV mortality Time to CV mortality CV mortality CV events Time to nonfatal MI Nonfatal MI Time to nonfatal stroke Nonfatal stroke Author, Year AURORA Fellstrom 2009 Multi 20 AURORA Fellstrom 2009 Multi 20 Median 4 y (2 y) Median 4 y (2 y) Description No. Analyzed (Enrolled) Results Control Control Rosuvastati n Rosuvastati n 1389 (1391) 1389 (1391) 1384 (1385) 1384 (1385) GFR or SCr CKD 5HD CKD 5HD (%) 21 (18) 21 (18) TC LDL HDL Tg 176 (174) 176 (174) 100 (99) 100 (99) 45 (45) 45 (45) 157 (154) 157 (154) Events 5.5/100 pt-y [6.0/100 pty] 248 (18%) [268 (19%)] 7.2/100 pt-y [7.3/100 pty] 324 (23%) [324 (23%)] 2.1/100 pt-y [2.5/100 pty] 91 (7%) [107 (8%)] 1.2/100 pt-y [1.1/100 pty] 53 (4%) [45 (3%)] RR/OR/HR (95% CI) P value Quality HR 0.92 (0.77, 1.09) HR 1.00 (0.85, 1.16) HR 0.84 (0.64, 1.11) HR 1.17 (0.79, 1.75) 29

30 Supplemental Table 12: Summary table of RCTs of statins vs. placebo in dialysis patients with a without [continuous outcomes] (Units) Dialysis with Lipid levels LDL, LDL, mmo/l Total cholesterol, mmol/l Dialysis without Lipid levels LDL, Total cholesterol, Triglycerides, HDL, LDL, Triglycerides, Author, Year 4D Wanner 2005 Germany 18 AURORA Holdaas subgp with Multi AURORA Fellstrom 2009 Multi 20 4 wk (2 y) (2 y) 3 mo (2 y) Median 4y (2 y) Description No. Analyzed (Enrolled) Results (Lipids) Control Control GFR or SCr Atorvastatin Rosuvastatin Rosuvastatin 619 (619) 44 (619) 388 ( (1391) 636 (636) 37 (636) 343 (343) 1384 (1385) CKD 5HD (%) 100 (100) CKD 5HD 100 CKD 5HD 21 (18) (Control) 125 (127) 2.51 (2.43) 4.49 (4.35) 100 (99) 176 (174) 157 (154) 45 (45) 147 (145) 165 (164) Final (Control) 72 (120) (92) 1.41 (2.43) 3.29 () 58 (97.1) 129 (173) 131 (155.8) 46.2 (44.6) 98 (135) (165) 82 (Control) -53 (-7) -55 (-35) () -42 (-1.9) -47 (-1) -26 (+1.8) +1.2 (+0.4) (-9.5) (+1) Net (95% CI) P value Quality < < < Estimated from figure 80 Estimated from graph 81 Study is graded however consider downgrading in EP due to the fact that there was no significant interaction of baseline egfr a treatment group. 82 Estimated from graph 83 Study is graded however consider downgrading in EP due to the fact that there was no significant interaction of baseline egfr a treatment group. 30

31 Supplemental Table 13: Evidence profile of RCTs examining the effect of statins vs. placebo in dialysis patients with a without Composite outcomes Mortality CV mortality CV events ESRD Kidney function (categorical) Lipid levels (continuous) Adverse events Total Non Non Non # of studies a study design 2 RCTs (High) 1 RCT (High 2 RCTs (High) 1 RCT (High 2 RCTs (High) 1 RCT (High 2 RCTs (High) Total N (treatment) 1986 (1007) 2773 (1389) 1986 (1007) 2773 (1389) 1986 (1007) 2773 (1389) 1790 (905) Methodological quality of studies per outcome No limitations No limitations No limitations No limitations No limitations No limitations No limitations Consistency across studies No important inconsistencies NA No important inconsistencies NA No important inconsistencies NA No important inconsistencies Directness of the evidence generalizability/ applicability Direct Direct Direct Direct Direct Direct Direct Other considerations None Sparse (-1) Sparse (-1) Sparse (-1) Sparse (-1) Sparse (-1) None Quality of evidence for outcome High Moderate Moderate Moderate Moderate Moderate Moderate Non 1 RCT 2773 No limitations Direct Sparse NA (High (1389) (-1) Moderate 0 RCTs Non 0 RCTs RCTs Non Non 0 RCTs RCTs (High) 1 RCT (High 1986 (1007) 2773 (1389) Some limitations (-1) No limitations RCTs (2396) RCTs (2396) Balance of potential benefits a harms: No difference No important inconsistencies NA Uncertainty about directness (-1) Uncertainty about directness (-1) None Sparse (-1) Low Low Summary of fiings Qualitative a quantitative description of effect No difference in patients with No difference in patients without No difference in patients with No difference in patients without Possible benefit from statins in patients with No difference in patients without Possible benefit from statins for patients with No difference in patients without Importance of outcome Critical Critical Critical Critical -- Critical -- High Benefit from statins in patients with Benefit from statins in patients without No difference in AEs for patients with a without Quality of overall evidence: Moderate Moderate Moderate 31

32 Supplemental Table 14: Summary table of RCT examining statin vs. placebo in patients with ADPKD [continuous outcomes] Lipid levels Total cholesterol, mmol/l LDL, mmol/l HDL, mmol/l Triglycerides, mmol/l Author, Year Fasset 2010 Australia 22 2 y (2 y) Description No. Analyzed (Enrolled) Control Control GFR or SCr Pravastatin 20 mg/day Control 29 (31) 20 (29) GFR 58.5 (49.9) ml/min/1.73 m 2 (%) (Control) 5.22 (4.91) 3.52 (3.08) 1.08 (1.38) 1.65 (1.19) Results (Lipids) Final (Control) 4.91 (4.95) 2.98 (2.92) 1.29 (1.50) 1.47 (1.30) (Control) (0.04) (-0.16) 0.10 (0.11) (0.11) Net (95% CI) P value Quality

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING

More information

JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014

JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014 JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss

More information

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,

More information

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181

More information

Statins and Risk for Diabetes Mellitus. Background

Statins and Risk for Diabetes Mellitus. Background Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration

More information

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and

More information

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University

More information

HYPERCHOLESTEROLAEMIA STATIN AND BEYOND

HYPERCHOLESTEROLAEMIA STATIN AND BEYOND HYPERCHOLESTEROLAEMIA STATIN AND BEYOND Andrea Luk Division of Endocrinology Department of Medicine & Therapeutics The Chinese University of Hong Kong HA Convention 4 May 2016 Statins reduce CVD and all-cause

More information

Individual Study Table Referring to Part of Dossier: Volume: Page:

Individual Study Table Referring to Part of Dossier: Volume: Page: 2.0 Synopsis AbbVie Inc. Name of Study Drug: Trilipix (ABT-335) Name of Active Ingredient: choline salt of fenofibric acid Individual Study Table Referring to Part of Dossier: Volume: Page: (For National

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

Evidence for Statins in

Evidence for Statins in Evidence for Statins in Secondary & Primary Prevention Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine (Cardiology) Co Director, Prevention Intervention Center University

More information

Primary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing

Primary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Primary Care Management of Women with Hyperlipidemia Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Objectives: Define dyslipidemia in women Discuss the investigation process leading

More information

Diabetic Nephropathy

Diabetic Nephropathy Diabetic Nephropathy Kidney disease is common in people affected by diabetes mellitus Definition Urinary albumin excretion of more than 300mg in a 24 hour collection or macroalbuminuria Abnormal renal

More information

Cardiovascular Risk in Diabetes

Cardiovascular Risk in Diabetes Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,

More information

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

HYPERTENSION ASSOCIATED WITH RENAL DISEASES RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein

More information

ASN DIALYSIS ADVISORY GROUP ASN DIALYSIS CURRICULUM

ASN DIALYSIS ADVISORY GROUP ASN DIALYSIS CURRICULUM ASN DIALYSIS ADVISORY GROUP ASN DIALYSIS CURRICULUM Management of Traditional Cardiovascular Risk Factors in ESRD (Hypertension, Dyslipidemia, Glycemic Control) ROBERT D. TOTO, M.D. PROFESSOR OF MEDICINE

More information

Statin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012)

Statin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012) Statin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012) Notes relating to this guidance This guidance serves

More information

Diabetes and the Kidneys

Diabetes and the Kidneys Diabetes and the Kidneys Aim(s) and objective(s) This guideline focuses on the detection, prevention, and management of kidney disease in people with diabetes. The management of end-stage renal disease

More information

Management of Lipids in 2015: Just Give them a Statin?

Management of Lipids in 2015: Just Give them a Statin? Management of Lipids in 2015: Just Give them a Statin? James H. Stein, M.D. Division of Cardiovascular Medicine University of Wisconsin School of Medicine and Public Health Stone NJ, et al. Circulation

More information

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk Lynne T Braun, PhD, CNP, FAHA, FAAN Professor of Nursing, Nurse Practitioner Rush University Medical Center 2

More information

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,

More information

Understanding diabetes Do the recent trials help?

Understanding diabetes Do the recent trials help? Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.

More information

BMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease.

BMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease. March 3, 2012 BD Response to FDA statement regarding Statins The Food and Drug Administration announced on Tuesday (February 28, 2012) the changes to the safety information on the labels of statins regarding

More information

Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland

Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland 14:00-14:55 WS #45: New Therapies for Lipid Management 15:05-16:00 WS #57: New Therapies for

More information

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years

More information

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering

More information

Drug Class Review on HMG-CoA Reductase Inhibitors (Statins)

Drug Class Review on HMG-CoA Reductase Inhibitors (Statins) Drug Class Review on HMG-CoA Reductase Inhibitors (Statins) Final Report September 2005 The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles

More information

Absolute cardiovascular disease risk

Absolute cardiovascular disease risk Guidelines for the management of Absolute cardiovascular disease risk An initiative of the National Vascular Disease Prevention Alliance About the National Vascular Disease Prevention Alliance The National

More information

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.

More information

Prognostic impact of uric acid in patients with stable coronary artery disease

Prognostic impact of uric acid in patients with stable coronary artery disease Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,

More information

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate

More information

Absolute cardiovascular disease risk management

Absolute cardiovascular disease risk management Quick reference guide for health professionals Absolute cardiovascular disease risk management This quick reference guide is for use by health professionals for primary prevention of cardiovascular disease

More information

High Blood Cholesterol

High Blood Cholesterol National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour

More information

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common

More information

Diabetes and Your Kidneys

Diabetes and Your Kidneys American Kidney Fund reaching out giving hope improving lives Diabetes and Your Kidneys reaching out giving hope improving lives Diabetes: The #1 Cause of Kidney Failure Your doctor told you that you have

More information

Estimated GFR Based on Creatinine and Cystatin C

Estimated GFR Based on Creatinine and Cystatin C Estimated GFR Based on Creatinine and Cystatin C Lesley A Stevens, MD, MS Tufts Medical Center, Tufts University School of Medicine Boston MA Chronic Kidney Disease-Epidemiology Collaboration UO1 DK 053869,

More information

Type of outcome measures: The search strategy MEDLINE (OVID)

Type of outcome measures: The search strategy MEDLINE (OVID) Types of participants: Inclusion criteria: Randomized controlled trials, examining effect of Renin-angiotensin system blockade on the renal and cardiovascular events in patients with chronic kidney disease

More information

Statins for Hyperlipidemia (High Cholesterol)

Statins for Hyperlipidemia (High Cholesterol) Statins for Hyperlipidemia (High Cholesterol) Examples of statin drugs Brand Name Mevacor Pravachol Zocor Lescol, Lescol XL Lipitor Crestor Chemical Name lovastatin pravastatin sodium simvastatin fluvastatin

More information

High Blood Pressure and Kidney Disease

High Blood Pressure and Kidney Disease High Blood Pressure and Kidney Disease National Kidney and Urologic Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH The kidneys play a key

More information

Special Communication

Special Communication Clinical Review & Education Special Communication 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National

More information

Many asymptomatic individuals

Many asymptomatic individuals Facts, myths and misconceptions about LDL-C and HDL-C By Michael B. Clearfield, DO Many asymptomatic individuals will succumb to cardiovascular disease (CVD), which is the leading cause of death and loss

More information

Guidelines for the management of hypertension in patients with diabetes mellitus

Guidelines for the management of hypertension in patients with diabetes mellitus Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes

More information

Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8)

Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) Adapted by Capital Health Plan Approved by Quality Improvement

More information

DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD

DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Elhami et al. SJIF Impact Factor 5.210 Volume 4, Issue 11, 1159-1166 Research Article ISSN 2278 4357 DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE

More information

Addendum to Clinical Review for NDA 22-512

Addendum to Clinical Review for NDA 22-512 Addendum to Clinical Review for DA 22-512 Drug: Sponsor: Indication: Division: Reviewers: dabigatran (Pradaxa) Boehringer Ingelheim Prevention of stroke and systemic embolism in atrial fibrillation Division

More information

Cardiovascular Disease in Diabetes

Cardiovascular Disease in Diabetes Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality

More information

LIVER FUNCTION TESTS AND STATINS

LIVER FUNCTION TESTS AND STATINS LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND: STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention

More information

Chronic Kidney Disease and Diabetes

Chronic Kidney Disease and Diabetes Anyone with diabetes can get kidney disease. Diabetes and high blood pressure are the most common causes of kidney disease, and people often have both. Chronic (long term) kidney disease (CKD) caused by

More information

Models of Chronic Kidney Disease Care and Initiation of Dialysis. Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK

Models of Chronic Kidney Disease Care and Initiation of Dialysis. Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK Models of Chronic Kidney Disease Care and Initiation of Dialysis Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK Early Crash Landings Talk Outline Pathways & Definitions Guideline recommendations

More information

Treatment Issues of Diabetes, Hypertension, and Lipids in the Elderly Patient

Treatment Issues of Diabetes, Hypertension, and Lipids in the Elderly Patient Treatment Issues of Diabetes, Hypertension, and Lipids in the Elderly Patient 17 th Primary Care Conference March 26, 2013 L. Brian Cross, PharmD, BCACP, CDE Chad K. Gentry, PharmD, BCACP, CDE Objectives

More information

Rivaroxaban for acute coronary syndromes

Rivaroxaban for acute coronary syndromes Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following

More information

Using multiple biomarkers to predict renal and cardiovascular drug efficacy: Implications for drug development and registration

Using multiple biomarkers to predict renal and cardiovascular drug efficacy: Implications for drug development and registration Using multiple biomarkers to predict renal and cardiovascular drug efficacy: Implications for drug development and registration Hiddo Lambers Heerspink Department of Clinical Pharmacology University Medical

More information

Renal Disease in Type 2 Diabetes Mellitus

Renal Disease in Type 2 Diabetes Mellitus Renal Disease in Type 2 Diabetes Mellitus 6th Collaborative DiGP/HSE/UCC Conference 25 th September 2013 Dr. Eoin O Sullivan Consultant Endocrinologist Bon Secours Hospital Cork Case 69 year old woman

More information

Identifying and treating long-term kidney problems (chronic kidney disease)

Identifying and treating long-term kidney problems (chronic kidney disease) Understanding NICE guidance Information for people who use NHS services Identifying and treating long-term kidney problems (chronic kidney disease) NICE clinical guidelines advise the NHS on caring for

More information

Using an EMR to Improve Quality of Care in a National Network

Using an EMR to Improve Quality of Care in a National Network Using an EMR to Improve Quality of Care in a National Network James M. Gill, MD, MPH Associate Professor of Family Medicine Senior Scientist in Health Policy Jefferson Medical College, Philadelphia, PA

More information

Renovascular Hypertension

Renovascular Hypertension Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working

GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National

More information

Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus

Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 84 Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus Summary Overview Clinical

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report by the panel appointed to the Eighth Joint National

More information

Chronic Kidney Disease and the Electronic Health Record. Duaine Murphree, MD Sarah M. Thelen, MD

Chronic Kidney Disease and the Electronic Health Record. Duaine Murphree, MD Sarah M. Thelen, MD Chronic Kidney Disease and the Electronic Health Record Duaine Murphree, MD Sarah M. Thelen, MD Definition of Chronic Kidney Disease (CKD) Defined by the National Kidney Foundation Either a decline in

More information

10/11/2014. Laura C. Halder, Pharm.D. Postgraduate Year Two Pharmacy Resident Cardiology Abbott Northwestern Hospital Allina Health October 30, 2014

10/11/2014. Laura C. Halder, Pharm.D. Postgraduate Year Two Pharmacy Resident Cardiology Abbott Northwestern Hospital Allina Health October 30, 2014 Laura C. Halder, Pharm.D. Postgraduate Year Two Pharmacy Resident Cardiology Abbott Northwestern Hospital Allina Health October 30, 2014 1 1. List two major changes to the 2013 cholesterol treatment guidelines.

More information

International Task Force for Prevention Of Coronary Heart Disease. Clinical management of risk factors. coronary heart disease (CHD) and stroke

International Task Force for Prevention Of Coronary Heart Disease. Clinical management of risk factors. coronary heart disease (CHD) and stroke International Task Force for Prevention Of Coronary Heart Disease Clinical management of risk factors of coronary heart disease and stroke Economic analyses of primary prevention of coronary heart disease

More information

Nierfunctiemeting en follow-up van chronisch nierlijden

Nierfunctiemeting en follow-up van chronisch nierlijden Nierfunctiemeting en follow-up van chronisch nierlijden 12 Jan 2016 Patrick Peeters, M.D. Dept Nephrology Ghent University Hospital Plan of presentation 1/ Renal function determination: Measured GFR Estimated

More information

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1

More information

Rx Updates New Guidelines, New Medications What You Need to Know

Rx Updates New Guidelines, New Medications What You Need to Know Rx Updates New Guidelines, New Medications What You Need to Know Maria Pruchnicki, PharmD, BCPS, BCACP, CLS Associate Professor of Clinical Pharmacy OSU College of Pharmacy Background scope and impact

More information

Overview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU

Overview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU Overview and update of modern type 2 Diabetes philosophy and management Dr Steve Stanaway Consultant Endocrinologist BCU Diabetes economics 2009: 2.6M adults with DM in UK (90% type 2) 2025: est. > 4M

More information

Update in Contrast Induced Nephropathy

Update in Contrast Induced Nephropathy Update in Contrast Induced Nephropathy Yves Pirson Service de Néphrologie, Clin. Univ. St-Luc - UCL A 76-year-old man with - type 2 diabetes - CKD (ser. creat.: 1.8 mg/dl; GFR: 32) presents with angina

More information

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell

More information

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,

More information

Guideline for Microalbuminuria Screening

Guideline for Microalbuminuria Screening East Lancashire Diabetes Network Guideline for Microalbuminuria Screening Produced by: Task and Finish Group, Clinical Standards Group Produced: August 2006 Approved by: East Lancashire Diabetes Network

More information

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen

More information

The contribution of chronic kidney disease to the global burden of major noncommunicable diseases

The contribution of chronic kidney disease to the global burden of major noncommunicable diseases http://www.kidney-international.org & 2011 International Society of Nephrology The contribution of chronic kidney disease to the global burden of major noncommunicable diseases William G. Couser 1, Giuseppe

More information

Correspondence to: Rima B Shah (rima_1223@yahoo.co.in) DOI: 10.5455/ijmsph.2013.2.167-172 Received Date: 29.11.2012 Accepted Date: 03.12.

Correspondence to: Rima B Shah (rima_1223@yahoo.co.in) DOI: 10.5455/ijmsph.2013.2.167-172 Received Date: 29.11.2012 Accepted Date: 03.12. RESEARCH ARTICLE STUDY OF UTILIZATION PATTERN OF ANTI-HYPERTENSIVE DRUGS IN HYPERTENSIVE DIABETIC PATIENTS WITH OR WITHOUT REDUCED RENAL FUNCTION AT TERTIARY CARE TEACHING HOSPITAL Jay Shah 1, Tejas Khakhkhar

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan

More information

High Cholesterol and Heart Disease

High Cholesterol and Heart Disease Evaluating statin drugs to treat: High Cholesterol and Heart Disease Comparing Effectiveness, Safety, and Price Contents Our Recommendations........................................... 3 Welcome....................................................

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 25 September 2008 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE

More information

Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)

Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic

More information

Cholesterol and Triglycerides What You Should Know

Cholesterol and Triglycerides What You Should Know Cholesterol and Triglycerides What You Should Know Michael T. McDermott MD Professor of Medicine Endocrinology Practice Director Division of Endocrinology, Metabolism and Diabetes University of Colorado

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better Marian Taylor, M.D. Medical University of South Carolina Director, Cardiac Rehabilitation I have no disclosures.

More information

Risk Factors of chronic complex co-morbidities. Aldo Pietro Maggioni, MD ANMCO Research Center Firenze, Italy

Risk Factors of chronic complex co-morbidities. Aldo Pietro Maggioni, MD ANMCO Research Center Firenze, Italy Risk Factors of chronic complex co-morbidities Aldo Pietro Maggioni, MD ANMCO Research Center Firenze, Italy Statement 1 In real world practice (and in clinical trials), complex co-morbidities are the

More information

CHRONIC KIDNEY DISEASE MANAGEMENT GUIDE

CHRONIC KIDNEY DISEASE MANAGEMENT GUIDE CHRONIC KIDNEY DISEASE MANAGEMENT GUIDE Outline I. Introduction II. Identifying Members with Kidney Disease III. Clinical Guidelines for Kidney Disease A. Chronic Kidney Disease B. End Stage Renal Disease

More information

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D. TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type

More information

Coding to be more efficient and accurate

Coding to be more efficient and accurate Why we need to code well! Coding to be more efficient and accurate Diabetes without Complication Diabetes with opthamologic or unspecified complication Diabetes with acute complication $1833 $2931 $3836

More information

Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires

Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Prof. J. Philippe Effect of estrogens on glucose metabolism : Fasting Glucose, HbA1c and C-Peptide

More information

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015 Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents

More information

Treatment Recommendations for CKD in Cats (2015)

Treatment Recommendations for CKD in Cats (2015) All treatments for chronic kidney disease (CKD) need to be tailored to the individual patient. The following recommendations are useful starting points for the majority of cats at each stage. Serial monitoring

More information

ADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE

ADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE I. PURPOSE To establish guidelines for the monitoring of antihypertensive therapy in adult patients and to define the roles and responsibilities of the collaborating clinical pharmacist and pharmacy resident.

More information

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:

More information

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical

More information

Chronic Kidney Disease (CKD) Algorithm. Chronic Kidney Disease (CKD) Algorithm Page 1

Chronic Kidney Disease (CKD) Algorithm. Chronic Kidney Disease (CKD) Algorithm Page 1 Chronic Kidney Disease (CKD) Algorithm Chronic Kidney Disease (CKD) Algorithm Page 1 Chronic Kidney Disease (CKD) Algorithm (See NICE Clinical Guideline CG73 1 and Quality Standards 2 ) Who should have

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare

More information

Definition, Prevalence, Pathophysiology and Complications of CKD. JM Krzesinski CHU Liège-ULg Core curriculum Nephrology September 28 th 2013

Definition, Prevalence, Pathophysiology and Complications of CKD. JM Krzesinski CHU Liège-ULg Core curriculum Nephrology September 28 th 2013 Definition, Prevalence, Pathophysiology and Complications of CKD JM Krzesinski CHU Liège-ULg Core curriculum Nephrology September 28 th 2013 KI supplements January 2013 Objectives of the course on CKD:

More information

Review Article. Indian J Med Res 138, October 2013, pp 461-491. Enas A. Enas, Arun Kuruvila, Pravien Khanna, C.S. Pitchumoni * & Viswanathan Mohan **

Review Article. Indian J Med Res 138, October 2013, pp 461-491. Enas A. Enas, Arun Kuruvila, Pravien Khanna, C.S. Pitchumoni * & Viswanathan Mohan ** Review Article Indian J Med Res 138, October 2013, pp 461-491 Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians A population with the highest risk of

More information

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for

More information

CDEC FINAL RECOMMENDATION

CDEC FINAL RECOMMENDATION CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) Indication: Stroke Prevention in Atrial Fibrillation This recommendation supersedes the Canadian Drug Expert Committee (CDEC) recommendation for

More information

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized

More information